Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First-line mCRC~* EGFR positive~* Bi-dimensional measurable index lesion~Exclusion Criteria:~* Previous exposure to EGFR-targeting therapy~* Previous oxaliplatin-based therapy~* Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment~* Radiotherapy~* Surgery~* Any other investigational drug in the 30 days before randomization~* Brain metastasis and/or leptomeningeal disease~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab Plus FOLFOX-4 (Type: EXPERIMENTAL): None
- FOLFOX-4 Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).